Modelling G-protein-coupled receptors for drug design

Biochimica et Biophysica Acta - Reviews on Biomembranes

Volumn 1422, Issue 3, 1999, Pages 207-234

  Flower, Darren R ^a,b  

^a ASTRA Charnwood ^*  (United Kingdom)

^b EDWARD JENNER INST FOR VACC RES   (United Kingdom)

Author keywords

Agonist; Antagonist; Drug design; G Protein coupled receptor; Molecular modeling; Mutagenesis

Indexed keywords

ATENOLOL; BUSPIRONE; CALCITONIN RECEPTOR; CELL SURFACE RECEPTOR; CIMETIDINE; CISAPRIDE; CYCLIC AMP RECEPTOR; DOXAZOSIN; FAMOTIDINE; GOSERELIN; GUANINE NUCLEOTIDE BINDING PROTEIN; IPRATROPIUM BROMIDE; LEUPRORELIN; LIGAND; LORATADINE; LOSARTAN; LOSARTAN POTASSIUM; MEMBRANE PROTEIN; METABOTROPIC RECEPTOR; METOPROLOL; NIZATIDINE; OLANZAPINE; PHEROMONE; RANITIDINE; RHODOPSIN; RISPERIDONE; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TERAZOSIN; UNINDEXED DRUG;

DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG TARGETING; MOLECULAR MODEL; PRIORITY JOURNAL; REVIEW; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS;

BINDING SITES; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; GTP-BINDING PROTEINS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTAGENESIS, SITE-DIRECTED; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, ANGIOTENSIN; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; SACCHAROMYCES CEREVISIAE PROTEINS;

EID: 0032735188     PISSN: 03044157     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-4157(99)00006-4     Document Type: Review

References (140)

1. S. Watson, S. Arkinstall, The G Protein Linked Receptors Facts Book, Academic Press, New York, 1994.
2. R.J. Lefkowitz, G protein-coupled receptors III. New roles for receptor kinases and arrestins in receptor signalling and desensitization, J. Biol. Chem. 273 (1998) 18677-18680.
3. T.K. Attwood, J.B. Findlay, Fingerprinting G-protein-coupled receptors, Protein Eng. 7 (1994) 195-203.
4. R. Henderson, G.F. Schertler, The structure of bacteriorhodopsin and its relevance to the visual opsins and other seven-helix G-protein coupled receptors, Phil. Trans. R. Soc. Lond. Ser. B Biol. Sci. 326 (1990) 379-389.
5. R. Henderson, J.M. Baldwin, T.A. Ceska, F. Zemlin, E. Beckmann, K.H. Downing, Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy, J. Mol. Biol. 213 (1990) 899-929.
6. D.R. Flower, Structural relationship of streptavidin to the calycin protein superfamily, FEBS Lett. 333 (1993) 99-102.
7. D.R. Flower, A.C. North, T.K. Attwood, Structure and sequence relationships in the lipocalins and related proteins, Protein Sci. 2 (1993) 753-761.
8. L.F. Kolakowski Jr., GCRDb: a G-protein-coupled receptor database, Recept. Channels 2 (1995) 1-7.
9. T. Gudermann, B. Nurnberg, G. Schultz, Receptors and G-proteins as primary components of transmembrane signal transduction, J. Mol. Med. 73 (1995) 51-63.
10. Data provided by 'IMS Health'
11. J.M. Stadel, S. Wilson, D.J. Bergsma, G. Orphan, Protein-coupled receptors: a neglected opportunity for pioneer drug discovery, Trends Pharmacol. Sci. 18 (1997) 430-437.
12. D.R. Littman, Chemokine receptors: keys to AIDS pathogenesis?, Cell 93 (1998) 677-680.
13. W.J. Dreyer, The area code hypothesis revisited - olfactory receptors and other related transmembrane receptors may function as the last digits in a cell surface code for assembling embryos, Proc. Natl. Acad. Sci. USA 95 (1998) 9072-9077.
14. C.D. Strader, T.M. Fong, M.R. Tota, D. Underwood, R.A. Dixon, Structure and function of G protein-coupled receptors, Annu. Rev. Biochem. 63 (1994) 101-132.
15. T.W. Schwartz, Locating ligand-binding sites in 7TM receptors by protein engineering, Curr. Opin. Biotechnol. 5 (1994) 434-444.
16. C.D. Strader, T.M. Fong, M.P. Graziano, M.R. Tota, The family of G-protein-coupled receptors, FASEB J. 9 (1995) 745-754.
17. A.G. Beck-Sickinger, Structural characterisation and binding sites of G-protein coupled receptors, Drug Discovery Today 1 (1996) 502-513.
18. J.A. Bikker, S. Trumppkallmeyer, C. Humblet, G-protein coupled receptors - models, mutagenesis, and drug design, J. Med. Chem. 41 (1998) 2911-2927.
19. T.K. Attwood, M.E. Beck, D.R. Flower, P. Scordis, J. Selley, The PRINTS protein fingerprint database in its fifth year, Nucleic Acids Res. 26 (1998) 304-308.
20. F. Horn, G. Vriend, G protein-coupled receptors in silico, J. Mol. Med. 76 (1998) 464-468.
21. T.K. Attwood, E.E. Eliopoulos, J.B.C. Findlay, Multiple sequence alignment of protein families showing low sequence homology: a methodological approach using database pattern-matching discriminators for G-protein-linked receptors, Gene 98 (1991) 153-159.
22. T.K. Attwood, J.B.C. Findlay, Design of a discriminating fingerprint for G-protein-coupled receptors, Protein Eng. 6 (1993) 167-176.
23. T.K. Attwood, H. Avison, M.E. Beck, M. Bewley, A.J. Bleasby, F. Brewster, P. Cooper, K. Degtyarenko, A.J. Geddes, D.R. Flower, M.P. Kelly, S. Lott, K.M. Measures, D.J. Parry-Smith, D.N. Perkins, P. Scordis, D. Scott, C. Worledge, The PRINTS database of protein fingerprints: a novel information resource for computational molecular biology, J. Chem. Inf. Comput. Sci. 37 (1997) 417-424.
24. M.S. Singer, L. Oliveira, G. Vriend, G.M. Shepherd, Potential ligand-binding residues in rat olfactory receptors identified by correlated mutation analysis, Recept. Channels 3 (1995) 89-95.
25. F. Horn, R. Bywater, G. Krause, W. Kuipers, L. Oliviera, A.C.M. Paiva, C. Sander, G. Vriend, The interaction of class B G protein-coupled receptors with their hormones, Recept. Channels 5 (1996) 305-314.
26. A.M. De Vos, M. Ultsch, A.A. Kossiakoff, Human growth hormone and extracellular domain of its receptor: crystal structure of the complex, Science 255 (1992) 306.
27. J.H. Naismith, T.Q. Devine, T. Kohno, S.R. Sprang, Structures of the extracellular domain of the type I tumor necrosis factor receptor, Structure 4 (1996) 1251-1262.
28. J. Deisenhofer, O. Epp, K. Miki, R. Huber, H. Michel, Structure of the protein subunits in the photosynthetic reaction centre of Rhodopseudomonas viridis at 3 angstroms resolution, Nature 318 (1985) 618.
29. M.S. Weiss, G.E. Schulz, Structure of porin refined at 1.8 angstroms resolution, J. Mol. Biol. 227 (1992) 493.
30. R. Henderson, J.M. Baldwin, T.A. Ceska, F. Zemlin, E. Beckmann, K.H. Downing, Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy, J. Mol. Biol. 213 (1990) 899.
31. E. Pebay-Peyroula, G. Rummel, J.P. Rosenbusch, E.M. Landau, X-ray structure of bacteriorhodopsin at 2.5 angstroms from microcrystals grown in lipidic cubic phases, Science 277 (1997) 1676-1681.
32. R. Grisshammer, C.G. Tate, Overexpression of integral membrane proteins for structural studies, Q. Rev. Biophys. 28 (1995) 315-422.
33. W. Kuhlbrandt, Two-dimensional crystallization of membrane proteins, Q. Rev. Biophys. 25 (1992) 1-49.
34. R. Grisshammer, J. Tucker, Quantitative evaluation of neurotensin receptor purification by immobilized metal affinity chromatography, Protein Expr. Purif. 11 (1997) 53-60.
35. E. Wilson-Kubalek, R. Brown, H. Celia, R. Milligan, Lipid nanotubes as substrates for helical crystallization of macromolecules, Proc. Natl. Acad. Sci. USA 95 (1998) 8040-8045.
36. D. Czajkowsky, Z. Shao, Submolecular resolution of single macromolecules with atomic force microscopy, FEBS Lett. 430 (1998) 51-54.
37. V.M. Unger, G.F. Schertler, Low resolution structure of bovine rhodopsin determined by electron cryo-microscopy, Biophys. J. 68 (1995) 1776-1786.
38. G.F. Schertler, P.A. Hargrave, Projection structure of frog rhodopsin in two crystal forms, Proc. Natl. Acad. Sci. USA 92 (1995) 11578-11582.
39. A. Davies, G.F. Schertler, B.E. Gowen, H.R. Saibil, Projection structure of an invertebrate rhodopsin, J. Struct. Biol. 117 (1996) 36-44.
40. V.M. Unger, P.A. Hargrave, J.M. Baldwin, G.F. Schertler, Arrangement of rhodopsin transmembrane alpha-helices, Nature 389 (1997) 203-206.
41. J.M. Baldwin, G.F. Schertler, V.M. Unger, An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors, J. Mol. Biol. 272 (1997) 144-164.
42. P.L. Yeagle, J.L. Alderfer, A.D. Albert, Structure of the third cytoplasmic loop of bovine rhodopsin, Biochemistry 34 (1995) 14621-14625.
43. P.L. Yeagle, J.L. Alderfer, A.D. Albert, Structure of the carboxy-terminal domain of bovine rhodopsin, Nat. Struct. Biol. 2 (1995) 832-834.
44. P.L. Yeagle, J.L. Alderfer, A.C. Salloum, L. Ali, A.D. Albert, The first and second cytoplasmic loops of the G-protein receptor, rhodopsin, independently form beta-turns, Biochemistry 36 (1997) 3864-3869.
45. P.L. Yeagle, J.L. Alderfer, A.D. Albert, Three-dimensional structure of the cytoplasmic face of the G protein receptor rhodopsin, Biochemistry 36 (1997) 9649-9654.
46. J. Lubkowski, G. Bujacz, L. Boque, P.J. Domaille, T.M. Handel, A. Wlodawer, The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions, Nat. Struct. Biol. 4 (1996) 64-69.
47. A.J. Lapthorn, D.C. Harris, A. Littlejohn, J.W. Lustbader, R.E. Canfield, K.J. Machin, F.J. Morgan, N.W. Isaacs, Crystal structure of human chorionic gonadotropin, Nature 369 (1994) 455-461.
48. D.G. Lambright, J. Sondek, A. Bohm, N.P. Skiba, H.E. Hamm, P.B. Sigler, The 2.0 A crystal structure of a heterotrimeric G protein, Nature 379 (1996) 311-319.
49. T. Iiri, Z. Farfel, H.R. Bourne, G-protein diseases furnish a model for the turn-on switch, Nature 394 (1998) 35-38.
50. J.B.C. Findlay, E.E. Eliopoulos, Three-dimensional modelling of G protein-linked receptors, Trends Pharmacol. Sci. 11 (1991) 492-499.
51. M.F. Hibert, S. Trumpp-Kallmeyer, A. Bruinvels, J. Hoflack, Three-dimensional models of neurotransmitter G- binding protein-coupled receptors, Mol. Pharmacol. 40 (1991) 8-15.
52. X.Q. Lewell, A model of the adrenergic beta-2 receptor and binding sites for agonist and antagonist, Drug Des. Discov. 9 (1992) 29-48.
53. J. Hoflack, S. Trumpp-Kallmeyer, M. Hibert, Re-evaluation of bacteriorhodopsin as a model for G protein-coupled receptors, Trends Pharmacol. Sci. 15 (1994) 7-9.
54. M.F. Hibert, S. Trumpp-Kallmeyer, J. Hoflack, A. Bruinvels, This is not a G protein-coupled receptor, Trends Pharmacol. Sci. 14 (1993) 7-12.
55. L. Pardo, J.A. Ballesteros, R. Osman, H. Weinstein, On the use of the transmembrane domain of bacteriorhodopsin as a template for modelling the three-dimensional structure of guanine nucleotide-binding regulatory protein-coupled receptors, Proc. Natl. Acad. Sci. USA 89 (1992) 4009-4012.
56. T.G. Metzger, M.G. Paterlini, P.S. Portoghese, D.M. Ferguson, An analysis of the conserved residues between halobacterial retinal proteins and G-protein coupled receptors: implications for GPCR modelling, J. Chem. Inf. Comput. Sci. 36 (1996) 857-861.
57. S.G. Dahl, O. Edvardsen, I. Sylte, Molecular dynamics of dopamine at the D2 receptor, Proc. Natl. Acad. Sci. USA 88 (1991) 8111-81115.
58. K.-C. Chou, L. Carlacci, G.M. Maggiora, L.A. Parodi, M.W. Schulz, An energy-based approach to packing the 7-helix bundle of bacteriorhodopsin, Protein Sci. 1 (1992) 810.
59. P.R. Gouldson, C.R. Snell, C.A. Reynolds, A new approach to docking in the beta 2-adrenergic receptor that exploits the domain structure of G-protein-coupled receptors, J. Med. Chem. 40 (1997) 3871-3886.
60. J.M. Baldwin, The probable arrangement of the helices in G protein-coupled receptors, EMBO J. 12 (1993) 1693-1703.
61. I.D. Pogozheva, A.L. Lomize, H.I. Mosberg, The transmembrane 7-alpha-bundle of rhodopsin: distance geometry calculations with hydrogen bonding constraints, Biophys. J. 72 (1997) 1963.
62. P. Herzyk, R.E. Hubbard, Combined biophysical and biochemical information confirms arrangement of transmembrane helices visible from the three-dimensional map of frog rhodopsin, J. Mol. Biol. 281 (1998) 741-754.
63. J.J. Perez, M. Filizola, M.A. Caritenifarina, General procedure for building the transmembrane domains of G-protein coupled receptors, J. Math. Chem. 23 (1998) 229-238.
64. http://www.lctn.u-nancy.fr/viseur/viseur.html; F. Campagne, J.M. Bernassau, B. Maigret.
65. M. Filizola, J.J. Perez, M. Cartenifarina, Bundle - a program for building the transmembrane domains of G-protein-coupled receptors, J. Computer-Aided Mol. Design 12 (1998) 111-118.
66. P. Herzyk, R.E. Hubbard, Automated method for modelling seven-helix transmembrane receptors from experimental data, Biophys. J. 69 (1995) 2419-2442.
67. M.C. Peitsch, P. Herzyk, T.N. Wells, R.E. Hubbard, Automated modelling of the transmembrane region of G-protein coupled receptor by Swiss-model, Recept. Channels 4 (1996) 161-164.
68. K. Kristiansen, S.G. Dahl, Ø. Edvardsen, A database of mutants and effects of site-directed mutagenesis experiments on G-protein coupled receptors, Proteins 26 (1996) 81-94.
69. C.D. Strader, I.S. Sigal, R.A. Dixon, Structural basis of beta-adrenergic receptor function, FASEB J. 3 (1989) 1825-1832.
70. M.R. Tota, M.R. Candelore, R.A. Dixon, C.D. Strader, Biophysical and genetic analysis of the ligand-binding site of the beta-adrenoceptor, Trends Pharmacol. Sci. 12 (1991) 4-6.
71. T.M. Savarese, C.M. Fraser, In vitro mutagenesis and the search for structure-function relationships among G protein-coupled receptors, Biochem. J. 283 (1992) 1-19.
72. T.M. Fong, C.D. Strader, Functional mapping of the ligand binding sites of G-protein coupled receptors, Med. Res. Rev. 14 (1994) 387-399.
73. C.D. Strader, I.S. Sigal, R.B. Register, M.R. Candelore, E. Rands, R.A. Dixon, Identification of residues required for ligand binding to the beta-adrenergic receptor, Proc. Natl. Acad. Sci. USA 84 (1987) 4384-4388.
74. R.A. Dixon, I.S. Sigal, E. Rands, R.B. Register, M.R. Candelore, A.D. Blake, C.D. Strader, Ligand binding to the beta-adrenergic receptor involves its rhodopsin-like core, Nature 326 (1987) 73-77.
75. C.D. Strader, I.S. Sigal, M.R. Candelore, E. Rands, W.S. Hill, R.A. Dixon, Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function, J. Biol. Chem. 63 (1988) 10267-10271.
76. C.D. Strader, M.R. Candelore, W.S. Hill, I.S. Sigal, R.A. Dixon, Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor, J. Biol. Chem. 264 (1989) 13572-13578.
77. M.R. Tota, C.D. Strader, Characterization of the binding domain of the beta-adrenergic receptor with the fluorescent antagonist carazolol. Evidence for a buried ligand binding site, J. Biol. Chem. 265 (1990) 16891-16897.
78. K. Wieland, H.M. Zuurmond, C. Krasel, A.P. Ijzerman, M.J. Lohse, Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor, Proc. Natl. Acad. Sci. USA 93 (1996) 9276-9281.
79. C.D. Strader, M.R. Candelore, W.S. Hill, R.A. Dixon, I.S. Sigal, A single amino acid substitution in the beta-adrenergic receptor promotes partial agonist activity from antagonists, J. Biol. Chem. 64 (1989) 16470-16477.
80. S. Suryanarayana, B.K. Kobilka, Amino acid substitutions at position 312 in the seventh hydrophobic segment of the beta 2-adrenergic receptor modify ligand-binding specificity, Mol. Pharmacol. 44 (1993) 111-114.
81. H. Kikkawa, M. Isogaya, T. Nagao, H. Kurose, The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005, Mol. Pharmacol. 53 (1998) 128-134.
82. S.A. Green, A.P. Spasoff, R.A. Coleman, M. Johnson, S.B. Liggett, Sustained activation of a G protein-coupled receptor via 'anchored' agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor, J. Biol. Chem. 271 (1996) 24029-24035.
83. R.A. Coleman, M. Johnson, A.T. Niais, C.J. Vardey, Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists, Trends Pharmacol. Sci. 17 (1996) 324-330.
84. 2-adrenoceptor agonists for the treatment of airways diseases, 1. The discovery and biological evaluation of some 7-(2-aminoethyl)-4-hydroxybenzothiazol-2(3H)-one analogues, J. Med. Chem., in press.
85. L. Hunyady, T. Balla, K.J. Catt, The ligand binding site of the angiotensin AT1 receptor, Trends Pharmacol. Sci. 17 (1996) 135-140.
86. Y. Inoue, N. Nakamura, T. Inagami, A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism, J. Hypertens. 15 (1997) 703-714.
87. Y. Yamano, K. Ohyama, S. Chaki, D.F. Guo, T. Inagami, Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site directed mutagenesis, Biochem. Biophys. Res. Commun. 187 (1992) 1426-1431.
88. S.A. Hjorth, H.T. Schambye, W.J. Greenlee, T.W. Schwartz, Identification of peptide binding residues in the extracellular domains of the AT1 receptor, J. Biol. Chem. 269 (1994) 30953-30959.
89. Y.H. Feng, K. Noda, Y. Saad, X.P. Liu, A. Husain, S.S. Karnik, The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism, J. Biol. Chem. 270 (1995) 12846-12850.
90. K. Noda, Y. Saad, S.S. Karnik, Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation, J. Biol. Chem. 270 (1995) 28511-28514.
91. H. Ji, M. Leung, Y. Zhang, K.J. Catt, K. Sandberg, Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan, J. Biol. Chem. 269 (1994) 16533-16536.
92. Y. Yamano, K. Ohyama, M. Kikyo, T. Sano, Y. Nakagomi, Y. Inoue, N. Nakamura, I. Morishima, D.F. Guo, T. Hamakubo et al., Mutagenesis and the molecular modelling of the rat angiotensin II receptor (AT1), J. Biol. Chem. 270 (1995) 14024-14030.
93. K. Noda, Y. Saad, A. Kinoshita, T.P. Boyle, R.M. Graham, A. Husain, S.S. Karnik, Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms, J. Biol. Chem. 270 (1995) 2284-2289.
94. H.T. Schambye, S.A. Hjorth, J. Weinstock, T.W. Schwartz, Interaction between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor, Mol. Pharmacol. 47 (1995) 425-431.
95. V. Nirula, W. Zheng, R. Sothinathan, K. Sandberg, Interaction of biphenylimidazole and imidazoleacrylic acid nonpeptide antagonists with valine 108 in TM III of the AT1 angiotensin receptor, Br. J. Pharmacol. 119 (1996) 1505-1507.
96. H. Ji, W. Zheng, Y. Zhang, K.J. Catt, K. Sandberg, Genetic transfer of a nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor, Proc. Natl. Acad. Sci. USA 92 (1995) 9240-9244.
97. V. Nirula, W. Zheng, K. Krishnamurthi, K. Sandberg, Identification of nonconserved amino acids in the AT1 receptor which comprise a general binding site for biphenylimidazole antagonists, FEBS Lett. 394 (1996) 361-364.
98. D. Dascal, V. Nirula, K. Lawus, S.E. Yoo, T.F. Walsh, K. Sandberg, Shared determinants of receptor binding for subtype selective, and dual endothelin-angiotensin antagonists on the AT1 angiotensin II receptor, FEBS Lett. 423 (1998) 15-18.
99. S. Perlman, H.T. Schambye, R.A. Rivero, W.J. Greenlee, S.A. Hjorth, T.W. Schwartz, Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor, J. Biol. Chem. 270 (1995) 1493-1496.
100. D.J. Underwood, C.D. Strader, R. Rivero, A.A. Patchett, W. Greenlee, K. Prendergast, Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor, Chem. Biol. 1 (1994) 211-221.
101. A.M. Lesk, C. Chothia, How different amino acid sequences determine similar protein structures: the structure and evolutionary dynamics of the globins, J. Mol. Biol. 136 (1980) 225-270.
102. E.J. Martin, J.M. Blaney, M.A. Siani, D.C. Spellmeyer, A.K. Wong, W.H. Moos, Measuring diversity - experimental-design of combinatorial libraries for drug discovery, J. Med. Chem. 38 (1995) 1431-1436.
103. N.F. Sepetov, V. Krchnak, M. Stankova, S. Wade, K.S. Lam, M. Lebl, Library of libraries: approach to synthetic combinatorial library design and screening of 'pharmacophore' motifs, Proc. Natl. Acad. Sci. USA 92 (1995) 5426-5430.
104. F.R. Salemme, J. Spurlino, R. Bone, Serendipity meets precision: the integration of structure-based drug design and combinatorial chemistry for efficient drug discovery, Structure 5 (1997) 319-324.
105. M.S. Chambers, R. Baker, D.C. Billington, A.K. Knight, D.N. Middlemiss, E.H. Wong, Spiropiperidines as high-affinity, selective sigma ligands, J. Med. Chem. 35 (1992) 2033-2039.
106. S.E. deLaszlo, F.E. Allen, B. Li, D. Ondeyka, R. Rivero, L. Malkowitz, C. Molineaux, S.J. Sciliano, M.S. Springer, W.J. Greenlee, S. Mantlo, A nonpeptide agonist of the human C5a receptor, Bioorg. Med. Chem. Lett. 7 (1997) 213-218.
107. R.P. Nargund, A.A. Patchett, M.A. Bach, M.G. Murphy, R.G. Smith, Peptidomimetic growth hormone secretagogues - design considerations and therapeutic potential, J. Med. Chem. 41 (1998) 3103-3127.
108. B.E. Evans, K.E. Rittle, M.G. Bock, R.M. DiPardo, R.M. Freidinger, W.L. Whitter, G.F. Lundell, D.F. Veber, P.S. Andersen, R.S. Chang, Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists, J. Med. Chem. 31 (1988) 2235-2246.
109. D. Donnelly, The arrangement of the transmembrane helices in the secretin receptor family of G-protein coupled receptors, FEBS Lett. 409 (1997) 431-436.
110. G. Costantino, R. Pellicciari, Homology modelling of metabotropic glutamate receptors. (mGluRs) structural motifs affecting binding modes and pharmacological profile of mGluR1 agonists and competitive antagonists, J. Med. Chem. 39 (1996) 3998-4006.
111. U. Gether, B.K. Kobilka, G protein coupled receptors II. Mechanism of agonist activation, J. Biol. Chem. 273 (1998) 17979-17982.
112. J. Wess, G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition, FASEB J. 11 (1997) 346-354.
113. D.L. Farrens, C. Altenbach, K. Yang, W.L. Hubbell, H.G. Khorana, Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin, Science 274 (1996) 768-770.
114. T.M. Fong, Mechanistic hypotheses for the activation of G-protein-coupled receptors, Cell. Signal. 8 (1996) 217-224.
115. U. Gether, S. Lin, P. Ghanouni, J.A. Ballesteros, H. Weinstein, B.K. Kobilka, Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor, EMBO J. 16 (1997) 6737-6747.
116. T.A. Spalding, E.S. Burstein, S.C. Henderson, K.R. Ducote, M.R. Brann, Identification of a ligand-dependent switch within a muscarinic receptor, J. Biol. Chem. 273 (1998) 21563-21568.
117. J. Ballesteros, S. Kitanovic, F. Guarnieri, P. Davies, B.J. Fromme, K. Konvicka, L. Chi, R.P. Millar, J.S. Davidson, H. Weinstein, S.C. Sealfon, Functional microdomains in G-protein-coupled receptors. The conserved arginine-cage motif in the gonadotropin-releasing hormone receptor, J. Biol. Chem. 273 (1998) 10445-10453.
118. A. Wise, I.C. Carr, D.A. Groarke, G. Milligan, Measurement of agonist efficacy using an alpha2A-adrenoceptor-Gi1alpha fusion protein, FEBS Lett. 419 (1997) 141-146.
119. A.R. Burt, M. Sautel, M.A. Wilson, S. Rees, A. Wise, G. Milligan, Agonist occupation of an alpha2A-adrenoreceptor-Gi1alpha fusion protein results in activation of both receptor-linked and endogenous Gi proteins. Comparisons of their contributions to GTPase activity and signal transduction and analysis of receptor-G protein activation stoichiometry, J. Biol. Chem. 273 (1998) 10367-10375.
120. P. Leff, C. Scaramellini, C. Law, K. McKechnie, A three-state receptor model of agonist action, Trends Pharmacol. Sci. 18 (1997) 355-362.
121. S. Robb, T.R. Cheek, F.L. Hannan, L.M. Hall, J.M. Midgley, P.D. Evans, Agonist-specific coupling of a cloned Drosophila octopamine/tyramine receptor to multiple second messenger systems, EMBO J. 13 (1994) 1325-1330.
122. D.M. Perez, J. Hwa, R. Gaivin, M. Mathur, F. Brown, R.M. Graham, Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor, Mol. Pharmacol. 49 (1996) 112-122.
123. H.J. Bohm, G. Klebe, What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs., Angewandte Chemie Int. Ed. (in English) 35 (22) (1996) 2589-2614.
124. B.K. Shoichet, I.D. Kuntz, Matching chemistry and shape in molecular docking, Protein Eng. 6 (1993) 223-232.
125. D.S. Goodsell, G.M. Morris, A.J. Olson, Docking of flexible ligands: applications of AutoDock, J. Mol. Recogn. 9 (1996) 1-5.
126. M. Rarey, B. Kramer, T. Lengauer, G. Klebe, Predicting receptor-ligand interactions by an incremental construction algorithm, J. Mol. Biol. 261 (1996) 470-489.
127. B.K. Shoichet, R.M. Stroud, D.V. Santi, I.D. Kuntz, K.M. Perry, Structure-based discovery of inhibitors of thymidylate synthase, Science 259 (1993) 1445-1450.
128. P. Burkhard, P. Taylor, M.D. Walkinshaw, An example of a protein ligand found by database mining: description of the docking method and its verification by a 2.3 A X-ray structure of a thrombin-ligand complex, J. Mol. Biol. 277 (1998) 449-466.
129. J. Janin, Elusive affinities, Proteins 21 (1995) 30-39.
130. J. Tokarski, A.J. Hopfinger, Constructing protein models for ligand-receptor binding thermodynamic simulations, J. Chem. Inf. Comput. Sci. 37 (1997) 779-791.
131. D. Horvath, A virtual screening approach applied to the search for trypanothione reductase inhibitors, J. Med. Chem. 40 (1997) 2412-2423.
132. A.R. Ortiz, M.T. Pisabarro, F. Gago, R.C. Wade, Prediction of drug binding affinities by comparative binding energy analysis, J. Med. Chem. 38 (1995) 2681-2691.
133. R.D. Head, M.L. Smythe, T.I. Oprea, C.L. Waller, S.M. Green, G.R. Marshall, VALIDATE - a new method for the receptor-based prediction of binding affinities of novel ligands, J. Am. Che. Soc. 118 (1996) 3959-3969.
134. A. Vedani, P. Zbinden, J.P. Snyder, Pseudo-receptor modelling: a new concept for the three-dimensional construction of receptor binding sites, J. Receptor Res. 13 (1993) 163-177.
135. P. Zbinden, M. Dobler, G. Folkers, A. Vedani, PRGEN -pseudoreceptor modelling using receptor-mediated ligand alignment and pharmacophore equilibration, Quant. Struc.-Activ. Relatsh. 17 (1998) 122-130.
136. D. Kocjan, On the interaction of the aromatic part of dopaminergic agonists with the receptor, J. Med. Chem. 37 (1994) 2851-2855.
137. Y. Sasaki, T. Chiba, Novel deltorphin heptapeptide analogs with potent delta agonist, delta antagonist, or mixed mu antagonist/delta agonist properties, J. Med. Chem. 38 (1995) 3995-3999.
138. H.S. Jae, M. Winn, D.B. Dixon, K.C. Marsh, B. Nguyen, T.J. Opgenorth, T.W. von Geldern, Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists, J. Med. Chem. 40 (1997) 3217-3227.
139. T. Taverne, O. Diouf, P. Depreux, J.H. Poupaert, D. Lesieur, B. Guardiola-Lemaitre, P. Renard, M.C. Rettori, D.H. Caignard, B. Pfeiffer, Novel benzothiazolin-2-one and benzoxazin-3-one arylpiperazine derivatives with mixed 5HT1A/D2 affinity as potential atypical antipsychotics, J. Med. Chem. 41 (1998) 2010-2018.
140. D.R. Flower, ALTER: eclectic management of molecular structure data, J. Mol. Graphics Model. 15 (1997) 161-169.